Drug Trial Radar · NCT05698524
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jun 26, 2023
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- University of NebraskaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Xynomic Pharmaceuticals, Inc.
- First posted
- Jan 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only 15%. Similarly, anaplastic astrocytoma and anaplastic oligodendroglioma, grade III gliomas, once recurrent after radiation therapy and first-line chemotherapy, have identical therapeutic options and poor outcomes with PFS-6 of 31%. Temozolomide (TMZ) has a favorable side effect profile and is available orally, however, cytotoxicity occurs. Metronomic temozolomide at low doses on a continuous schedule, have demonstrated better survival in studies. This study will determine the recommended dose and the side effects of PCI-24781/Abexinostat with metronomic temozolomide.
Conditions
- Recurrent High Grade Glioma
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Glioblastoma
- Gliosarcoma
Interventions
PCI 24781Drug
Participants will take PCI-24781/Abexinostat on days 1 - 4, 8 - 11, and 15 - 18 of each 28-day cycle.
TemozolomideDrug
Participants will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Toxicities Associated with PCI-24781/Abexinostat and Metronomic Temozolomide Therapy - Adverse Events and Serious Adverse EventsTime frame: Up to 25 months
- Toxicities Associated With PCI-24781/Abexinostat and Metronomic Temozolomide Therapy - OverallTime frame: Up to 25 months
- Recommended Dose Determination of PCI-24781/AbexinostatTime frame: Up to 20 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.